Nabiximols for the Treatment of Cannabis Dependence
2019 · JAMA Internal Medicine · 97 citations
https://doi.org/10.1001/jamainternmed.2019.1993
M
Mark Montebello
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
937
Citations
15
h-index
18
i10-index
Mark Montebello is an academic researcher from The University of Sydney. The author has contributed to research in topics: Substance Abuse Treatment and Outcomes & Cannabis and Cannabinoid Research & Opioid Use Disorder Treatment. The author has an h-index of 15, co-authored 48 publications.
ORCID: 0000-0002-1776-3974Papers by this author
works96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial
2024 · International Journal of Drug Policy · 15 citations
https://doi.org/10.1016/j.drugpo.2024.104390
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
2024 · BMC Psychiatry · 10 citations
https://doi.org/10.1186/s12888-024-05616-3
Additional file 2 of Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
2022 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.21303200
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat